Tag Archives: Schering Plough

Merck/Schering-Plough Merger Highlights (Update 1)

By George Koroneos | Published: March 9, 2009
Merck and Schering-Plough’s CEOs are giving a run down of the benefits of the $41.1 billion merger, announced this morning, in a conference call with investors. Here are some of the highlights: • Total price of the sale will be $41.1 billion or $23.6 per Schering share. • This deal is structured as a reverse merger with [...]
Posted in Deals, Strategy | Also tagged , , , , , | 4 Comments

Schering-Plough to Merge with Merck for $41.1 Billion

By George Koroneos | Published: March 9, 2009
Merck’s Richard T. Clark Image via Wikipedia Merck announced, a little over an hour ago, that it had signed an agreement with Schering-Plough’s board of directors to merge the two companies under the Merck name. The stock and cash transaction is worth over $41 billion with Schering shareholders receiving $10.50 per share in cash and 0.5767 of a [...]
Posted in Deals | Also tagged , , , , | Leave a comment

FDA Declares: Keep Taking Your Vytorin

By George Koroneos | Published: January 9, 2009
It’s official. Vytorin (ezetimibe/simvastatin) still does what it’s supposed to do—significantly decrease LDL cholesterol. FDA, yesterday, released its assessment of the now-notorious ENHANCE trial—which tested whether Vytorin was better than simvastatin alone in reducing arterial plaque in a group of patients with severe genetic high cholesterol. It wasn’t, and publication of the study set off a [...]
Posted in Regulatory | Also tagged , , , , , | 1 Comment